title: Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
abstract: A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.
authors.affiliation: Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
authors.forename: Shari
authors.initials: S
authors.lastname: Pilon-Thomas
authors.forename: Lisa
authors.initials: L
authors.lastname: Kuhn
authors.forename: Sabine
authors.initials: S
authors.lastname: Ellwanger
authors.forename: William
authors.initials: W
authors.lastname: Janssen
authors.forename: Erica
authors.initials: E
authors.lastname: Royster
authors.forename: Suroosh
authors.initials: S
authors.lastname: Marzban
authors.forename: Ragini
authors.initials: R
authors.lastname: Kudchadkar
authors.forename: Jonathan
authors.initials: J
authors.lastname: Zager
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Gibney
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Weber
authors.forename: James J
authors.initials: JJ
authors.lastname: Mulé
authors.forename: Amod A
authors.initials: AA
authors.lastname: Sarnaik
mesh_terms: D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D007376:Interleukin-2; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine